Research programme: HIV Vpr-based cancer therapy - Inovio

Drug Profile

Research programme: HIV Vpr-based cancer therapy - Inovio

Alternative Names: VGX-100 - Inovio; VGX-150

Latest Information Update: 30 Apr 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VGX Pharmaceuticals
  • Class
  • Mechanism of Action Apoptosis stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gastric cancer; Lymphoma; Malignant melanoma

Most Recent Events

  • 30 Apr 2012 Discontinued - Preclinical for Gastric cancer in USA (unspecified route)
  • 30 Apr 2012 Discontinued - Preclinical for Lymphoma in USA (unspecified route)
  • 30 Apr 2012 Discontinued - Preclinical for Malignant melanoma in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top